| Is your age between 18 yrs and 120 yrs? |
|
|
|
| Gender: Male or Female |
|
|
|
| Do you have any of these conditions: Renal Cell Carcinoma or Renal Cell Cancer? |
|
|
|
| Do you have any of these conditions: Renal Cell Cancer or Renal Cell Carcinoma? |
|
|
|
| Do you have any of these conditions: Renal Cell Carcinoma or Renal Cell Cancer? |
|
|
|
| Do you have any of these conditions: Renal Cell Cancer or Renal Cell Carcinoma? |
|
|
|
| Do you have any of these conditions: Renal Cell Cancer or Renal Cell Carcinoma? |
|
|
|
| Do you have any of these conditions: Renal Cell Cancer or Renal Cell Carcinoma? |
|
|
|
| Do you have any of these conditions: Renal Cell Cancer or Renal Cell Carcinoma? |
|
|
|
| Do you have any of these conditions: Renal Cell Carcinoma or Renal Cell Cancer? |
|
|
|
| Do you have any of these conditions: Renal Cell Cancer or Renal Cell Carcinoma? |
|
|
|
| Do you have any of these conditions: Renal Cell Carcinoma or Renal Cell Cancer? |
|
|
|
| Do you have any of these conditions: Renal Cell Carcinoma or Renal Cell Cancer? |
|
|
|
| Do you have any of these conditions: Renal Cell Cancer or Renal Cell Carcinoma? |
|
|
|
| Has a histologically confirmed diagnosis of locally advanced/metastatic ccRCC |
|
|
|
| Has experienced disease progression on or after having received systemic treatment for locally advanced or metastatic RCC with a PD-(L)1 checkpoint inhibitor (in sequence or in combination with a vascular endothelial growth factor - tyrosine kinase inhibitor [VEGF-TKI]) where PD-(L)1 checkpoint inhibitor treatment progression is defined by meeting ALL of the following criteria: (a) has received 2 doses of an anti-PD-(L)1 monoclonal antibody (mAb) (b) has shown radiographic disease progression during or after an anti-PD-(L)1 mAb as defined by RECIST 1.1 by investigator (c) disease progression has been documented within 12 weeks from the last dose of an anti-PD-(L)1 mAb |
|
|
|
| Has experienced disease progression on or after having received systemic treatment for locally advanced or metastatic RCC with a VEGF-TKI (in sequence or in combination with a PD-[L]1 checkpoint inhibitor) where VEGF-TKI treatment progression is defined by meeting the following criterion: has shown radiographic disease progression during or after a treatment with a VEGF-TKI as defined by RECIST 1.1 by investigator |
|
|
|
| Is able to swallow oral medication |
|
|
|
| Has adequate organ function |
|
|
|
| Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks before randomization/allocation |
|
|
|
| Has resolution of toxic effects of the most recent prior therapy to Grade 1 |
|
|
|
| If participants receive major surgery or radiation therapy, they must have recovered from complications from the intervention |
|
|
|
| Has adequately controlled blood pressure (BP 150/90 mm Hg) with no change in hypertensive medications within 1 week before randomization/allocation |
|
|
|
| Male participants are abstinent from heterosexual intercourse or agree to use contraception during treatment with and for at least 7 days after the last dose of lenvatinib and /or belzutifan; 7 days after lenvatinib and/or belzutifan is stopped, if the participant is only receiving pembrolizumab, pembrolizumab/quavonlimab, MK-4280A, MK-4830 or a combination of the aforementioned drugs, no contraception is needed |
|
|
|
| Female participant is not pregnant or breastfeeding and is not a woman of childbearing potential (WOCBP) or is a WOCBP abstinent from heterosexual intercourse or using contraception during the intervention period and for at least 120 days after the last dose of pembrolizumab, pembrolizumab/quavonlimab, MK-4280A, MK-4830 or 30 days after the last dose of lenvatinib or belzutifan, whichever occurs last |
|
|
|
| Has urine protein 1 g/24 hours and has any of the following: (a) hypoxia defined as a pulse oximeter reading <92% at rest, or (b) requires intermittent supplemental oxygen, or (c) requires chronic supplemental oxygen |
|
|
|
| Has clinically significant cardiovascular disease within 12 months from the first dose of study intervention administration |
|
|
|
| Has had major surgery within 3 weeks before first dose of study interventions |
|
|
|
| Has a history of lung disease |
|
|
|
| Has a history of inflammatory bowel disease |
|
|
|
| Has preexisting gastrointestinal (GI) or non-GI fistula |
|
|
|
| Has malabsorption due to prior GI surgery or disease |
|
|
|
| Has previously received treatment with a combination of pembrolizumab plus lenvatinib |
|
|
|
| Has received prior treatment with belzutifan |
|
|
|
| Has received prior radiotherapy within 2 weeks of start of study intervention |
|
|
|
| Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention; killed vaccines are allowed |
|
|
|
| Has received more than 4 previous systemic anticancer treatment regimens |
|
|
|
| Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive therapy within 7 days prior to the first dose of study intervention |
|
|
|
| Has known additional malignancy that is progressing or has required active treatment within the past 3 years |
|
|
|
| Has known central nervous system (CNS) metastases and/or carcinomatous meningitis |
|
|
|
| Has an active autoimmune disease that has required systemic treatment in the past 2 years; replacement therapy is not considered a form of systemic treatment and is allowed |
|
|
|
| Has an active infection requiring systemic therapy |
|
|
|
| Has a known history of human immunodeficiency virus (HIV) infection |
|
|
|
| Has a known history of Hepatitis B |
|
|
|
| Has had an allogenic tissue/solid organ transplant |
|
|
|